The Week in Review: Tigermed and ICON Form China CRO Partnership

Tigermed Consulting formed a China clinical CRO alliance with a global partner, ICON; MicuRx Pharma and Cumencor Pharma will collaborate with Pfizer on drug-resistant TB; Tongjitang Chinese Medicines (同济堂药业) received a buy-out offer from its Chairman and Fosun Industrial; Pfizer will focus its Singapore clinical research unit on Asia-specific diseases; Cord Blood America licensed its umbilical cord blood technology to AXM Pharma of China; Simcere (先声药业) said a recent acquisition committed fraud before Simcere purchased its controlling interest; the China subsidiary of NeoStem received SFDA approval to produce a generic antibiotic; and Sinovac (北京科兴生物制品有限公司) released very positive 2009 financial results. More details… Stock Symbols: (NSDQ: ICLR) (NYSE: PFE) (NYSE: TCM) (OTCBB: CBAI) (OTCPK: AXMP) (NYSE: SCR) (NYSE Amex: NBS) (NSDQ: SVA)